SOURCE: Paragon Financial Limited

Paragon Financial Limited

February 15, 2012 08:20 ET

Biotech Stocks Outperforming the Market -- Dendreon Corporation and Complete Genomics Shares on the Upswing

The Paragon Report Provides Equity Research on Dendreon Corporation & Complete Genomics

NEW YORK, NY--(Marketwire - Feb 15, 2012) - Biotech stocks have been on an impressive run in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. The iShares Nasdaq Biotechnology Index Fund -- which contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals -- is up more than 16 percent this year. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN) and Complete Genomics Inc. (NASDAQ: GNOM). Access to the full company reports can be found at:

www.paragonreport.com/DNDN

www.paragonreport.com/GNOM

Earlier this month The Food and Drug Administration (FDA) released its much anticipated guidelines for the sale of lower-cost versions of biotechnology drugs, which required studies showing that the generic copies are "highly similar" to the originals, but there are several ways that might be proven. According to market analysis firm Datamonitor, the worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as more than 30 branded biologics with sales of $51 billion lose patent exclusivity.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Shares of Complete Genomics skyrocketed more than 40 percent earlier this week after the company said in a statement that it had been selected to provide the Mayo Clinic with genome sequencing services. Under the agreement, the company will sequence and analyze genetic material for the Mayo Clinic's Center for Individualized Medicine. The Mayo Clinic will continue to operate and invest in its own sequencing lab.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. Dendreon's management will host a conference call on Monday, February 27, 2012 to review fourth quarter and year-end financial results.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer